Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 37.61
SRPT's Cash to Debt is ranked higher than
72% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SRPT: 37.61 )
SRPT' s 10-Year Cash to Debt Range
Min: 5.53   Max: No Debt
Current: 37.61

Equity to Asset 0.90
SRPT's Equity to Asset is ranked higher than
92% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SRPT: 0.90 )
SRPT' s 10-Year Equity to Asset Range
Min: -0.09   Max: 0.98
Current: 0.9

-0.09
0.98
F-Score: 2
Z-Score: 9.44
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -986.69
SRPT's Operating margin (%) is ranked higher than
57% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. SRPT: -986.69 )
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87   Max: -71.16
Current: -986.69

-28680.87
-71.16
Net-margin (%) -810.89
SRPT's Net-margin (%) is ranked higher than
58% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. SRPT: -810.89 )
SRPT' s 10-Year Net-margin (%) Range
Min: -27020   Max: -4.93
Current: -810.89

-27020
-4.93
ROE (%) -38.26
SRPT's ROE (%) is ranked higher than
72% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. SRPT: -38.26 )
SRPT' s 10-Year ROE (%) Range
Min: -309.2   Max: -16.44
Current: -38.26

-309.2
-16.44
ROA (%) -32.79
SRPT's ROA (%) is ranked higher than
71% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SRPT: -32.79 )
SRPT' s 10-Year ROA (%) Range
Min: -184.14   Max: -4.62
Current: -32.79

-184.14
-4.62
ROC (Joel Greenblatt) (%) -533.09
SRPT's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. SRPT: -533.09 )
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075   Max: -277.71
Current: -533.09

-2075
-277.71
Revenue Growth (%) -35.80
SRPT's Revenue Growth (%) is ranked higher than
63% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. SRPT: -35.80 )
SRPT' s 10-Year Revenue Growth (%) Range
Min: -63.2   Max: 383.5
Current: -35.8

-63.2
383.5
EBITDA Growth (%) 35.80
SRPT's EBITDA Growth (%) is ranked higher than
96% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. SRPT: 35.80 )
SRPT' s 10-Year EBITDA Growth (%) Range
Min: -36.3   Max: 43.4
Current: 35.8

-36.3
43.4
EPS Growth (%) 23.90
SRPT's EPS Growth (%) is ranked higher than
90% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SRPT: 23.90 )
SRPT' s 10-Year EPS Growth (%) Range
Min: -62.4   Max: 46.9
Current: 23.9

-62.4
46.9
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SRPT Guru Trades in Q4 2013

Columbia Wanger 2,635,000 sh (+84.14%)
Steven Cohen 711,777 sh (-25.88%)
George Soros 233,000 sh (-64.98%)
» More
Q1 2014

SRPT Guru Trades in Q1 2014

Columbia Wanger 2,633,000 sh (-0.08%)
Steven Cohen 641,600 sh (-9.86%)
George Soros 25,000 sh (-89.27%)
» More
Q2 2014

SRPT Guru Trades in Q2 2014

George Soros 680,000 sh (+2620%)
Columbia Wanger 2,633,000 sh (unchged)
Steven Cohen 272,100 sh (unchged)
» More
Q3 2014

SRPT Guru Trades in Q3 2014

Columbia Wanger 3,237,000 sh (+22.94%)
Steven Cohen 691,200 sh (unchged)
Steven Cohen 227,300 sh (-16.46%)
George Soros 325,000 sh (-52.21%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Reduce -52.21%0.08%$19.9 - $30.27 $ 16.52-26%325000
George Soros 2014-06-30 Add 2620%0.14%$22.18 - $38.91 $ 16.52-48%680000
George Soros 2014-03-31 Reduce -89.27%0.04%$17.91 - $30.29 $ 16.52-35%25000
George Soros 2013-12-31 Reduce -64.98%0.22%$12.89 - $53.81 $ 16.52-44%233000
Andreas Halvorsen 2013-09-30 Sold Out 0.14%$30.906 - $47.97 $ 16.52-57%0
George Soros 2013-09-30 Add 56.28%0.12%$30.906 - $47.97 $ 16.52-57%665274
Andreas Halvorsen 2013-03-31 New Buy0.15%$23.97 - $36.95 $ 16.52-43%690731
George Soros 2013-03-31 Add 82.54%0.08%$23.97 - $36.95 $ 16.52-43%413329
George Soros 2012-12-31 Add 184.13%0.05%$14.99 - $44.93 $ 16.52-38%226429
Jean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6 $ 16.52173%0
Jean-Marie Eveillard 2011-12-31 Reduce -83.33%$3.24 - $6.54 $ 16.52228%50000
Jean-Marie Eveillard 2011-09-30 Add 50%$6.3 - $9.9 $ 16.52109%300000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.30
SRPT's P/B is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. SRPT: 2.30 )
SRPT' s 10-Year P/B Range
Min: 1.61   Max: 234
Current: 2.3

1.61
234
P/S 51.60
SRPT's P/S is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. SRPT: 51.60 )
SRPT' s 10-Year P/S Range
Min: 1.56   Max: 310
Current: 51.6

1.56
310
EV-to-EBIT -3.64
SRPT's EV-to-EBIT is ranked higher than
59% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SRPT: -3.64 )
SRPT' s 10-Year EV-to-EBIT Range
Min: -29.1   Max: -0.8
Current: -3.64

-29.1
-0.8
Current Ratio 11.87
SRPT's Current Ratio is ranked higher than
89% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SRPT: 11.87 )
SRPT' s 10-Year Current Ratio Range
Min: 0.76   Max: 36.25
Current: 11.87

0.76
36.25
Quick Ratio 11.87
SRPT's Quick Ratio is ranked higher than
90% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SRPT: 11.87 )
SRPT' s 10-Year Quick Ratio Range
Min: 0.76   Max: 36.25
Current: 11.87

0.76
36.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.30
SRPT's Price/Net Cash is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. SRPT: 3.30 )
SRPT' s 10-Year Price/Net Cash Range
Min: 3.01   Max: 72.6
Current: 3.3

3.01
72.6
Price/Net Current Asset Value 3.30
SRPT's Price/Net Current Asset Value is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. SRPT: 3.30 )
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.96   Max: 115.5
Current: 3.3

2.96
115.5
Price/Tangible Book 2.40
SRPT's Price/Tangible Book is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. SRPT: 2.40 )
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41   Max: 474
Current: 2.4

2.41
474
Price/Median PS Value 2.00
SRPT's Price/Median PS Value is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. SRPT: 2.00 )
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 76.32
Current: 2

0.08
76.32
Earnings Yield (Greenblatt) -27.10
SRPT's Earnings Yield (Greenblatt) is ranked higher than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. SRPT: -27.10 )
SRPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -27.1   Max: 0
Current: -27.1

-27.1
0
Forward Rate of Return (Yacktman) 19.98
SRPT's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. SRPT: 19.98 )
SRPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -106.2   Max: 21.1
Current: 19.98

-106.2
21.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AB3A.Germany
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for NAS:SRPT

Headlines

Articles On GuruFocus.com
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
It was another slow, low volume, lackluster trading session Nov 24 2014
Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy... Nov 24 2014
BioMarin's Prosensa Buy: A 'Courageous' Acquisition? Nov 24 2014
BioMarin Buys Prosensa Backs Up Troubled Drug Nov 24 2014
Stock Futures Trending Higher; Kate Spade Bags An Upgrade Nov 24 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 24 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 24 2014
6:25 am Sarepta Therapeutics: Prosensa Holding (RNA) being bought... Nov 24 2014
Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant... Nov 21 2014
Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT)... Nov 18 2014
Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant... Nov 18 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Nov 14 2014
SAREPTA THERAPEUTICS, INC. Financials Nov 14 2014
Sarepta Initiates Dosing for Study Evaluating Eteplirsen Nov 13 2014
A Day Of Reckoning Approaches For Merck And Its Critics Nov 13 2014
Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients... Nov 12 2014
Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients... Nov 12 2014
INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg... Nov 11 2014
Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate... Nov 11 2014
SHAREHOLDER ALERT: Investigation on Behalf of Sarepta Therapeutics, Inc. Investors Announced by Law... Nov 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK